Stock ALINT INTEGRAGEN
Add to a list
To use this feature you must be a member
Log inSign up

Financials IntegraGen

Equities

ALINT

FR0010908723

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 09:05:14 26/04/2024 pm IST 		5-day change 1st Jan Change
0.59 EUR -1.67% Intraday chart for IntegraGen -9.23% -34.00%
2023 IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 IntegraGen SA Announces Revenue Results for the First Half of 2023 CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020
Capitalization 1 17.05 16.5 7.197 6.536 13.61
Enterprise Value (EV) 1 15.82 12.9 3.768 4.017 10.5
P/E ratio -10.3 x -19.1 x -6.3 x -23 x -36.6 x
Yield - - - - -
Capitalization / Revenue 2.72 x 2.53 x 1.04 x 0.79 x 1.51 x
EV / Revenue 2.52 x 1.98 x 0.54 x 0.49 x 1.17 x
EV / EBITDA -9.45 x -7.14 x -3.61 x -37.6 x -375 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 13.3 x 4.19 x 2.57 x 2.61 x 6.28 x
Nbr of stocks (in thousands) 5,030 6,495 6,484 6,471 6,638
Reference price 2 3.390 2.540 1.110 1.010 2.050
Announcement Date 28/04/17 27/04/18 01/03/19 03/04/20 11/06/21
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020
Net sales 1 6.272 6.509 6.951 8.28 9
EBITDA 1 -1.673 -1.807 -1.043 -0.107 -0.028
EBIT 1 -1.779 -1.93 -1.179 -0.3631 -0.255
Operating Margin -28.36% -29.65% -16.97% -4.38% -2.83%
Earnings before Tax (EBT) 1 -1.921 -1.195 -1.333 -0.4379 -0.467
Net income 1 -1.651 -0.8622 -1.14 -0.2848 -0.375
Net margin -26.32% -13.25% -16.4% -3.44% -4.17%
EPS 2 -0.3289 -0.1330 -0.1763 -0.0439 -0.0559
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 28/04/17 27/04/18 01/03/19 03/04/20 11/06/21
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020
Net Debt 1 - - - - -
Net Cash position 1 1.23 3.59 3.43 2.52 3.11
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) -78.3% -33.1% -33.9% -10.7% -16%
ROA (Net income/ Total Assets) -13.7% -14.9% -8.55% -2.96% -2.05%
Assets 1 12.03 5.803 13.32 9.622 18.32
Book Value Per Share 2 0.2600 0.6100 0.4300 0.3900 0.3300
Cash Flow per Share 2 0.1100 0.2100 0.1100 0.1800 0.7700
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 28/04/17 27/04/18 01/03/19 03/04/20 11/06/21
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
INTEGRAGEN Stock IntegraGen
-34.00% 4.18M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. ALINT Stock
  4. Financials IntegraGen